Dianthus Therapeutics, Inc.
DNTH
$24.33
$0.923.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.18% | -3.77% | -12.97% | -42.98% | -28.07% |
| Total Depreciation and Amortization | -157.14% | 70.51% | -73.01% | 566.13% | -157.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.58% | 154.55% | 31.50% | -64.27% | 88.00% |
| Change in Net Operating Assets | 283.52% | -294.08% | -116.24% | 799.31% | 110.26% |
| Cash from Operations | 13.53% | -0.68% | -29.04% | -46.39% | 2.76% |
| Capital Expenditure | -91.67% | 22.58% | -24.00% | -47.06% | 46.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.78% | 164.21% | 91.10% | -21,966.69% | 121.66% |
| Cash from Investing | 78.75% | 164.02% | 91.09% | -22,286.83% | 121.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 252.80% | -99.59% | 13,304.05% | 529.79% | -99.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 81.94% |
| Cash from Financing | 252.80% | -99.59% | 13,304.05% | 113.48% | -101.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.62% | -16.52% | 96.12% | -1,702.22% | -107.88% |